CIK细胞治疗急性白血病疗效的Meta分析研究.doc

华 中 科 技 大 学 硕 士 学 位 论 文 治疗组 263 例；AML 患者 377 例，ALL 患者 150 例。结果显示化疗/移植联合 CIK 细胞治疗 AL 患者与非 CIK 治疗组相比，各个研究至随访截止时 CIK 治疗 组总体生存率较非 CIK 治疗组提高 20%[ RD=0.20, 95%CI(0.07,0.32), P=0.003]； 而且能明显降低 AL 患者疾病复发率 [RR=0.38, 95%CI(0.25,0.59), P﹤0.0001]； 同时 CIK 治疗组能降低 AL 患者疾病死亡发生率 [RR=0.42, 95%CI(0.28,0.62), P ﹤0.0001]，并且 CIK 细胞治疗副作用小，安全性较好。 结论 现有 Meta 分析研究显示，化疗/移植联合 CIK 细胞辅助治疗 AL 患者与非 CIK 治疗组相比，使其总体生存率提高了约 20%，发生疾病复发的风险与非 CIK 治疗组相比降低了约 62%，发生死亡的风险与非 CIK 治疗组相比降低了约 58%， 同时 CIK 治疗副作用小安全性好。这一结论可以指导临床上 CIK 细胞有选择性 的用于难治和复发或有类似倾向的急性白血病患者的治疗，以降低 AL 疾病复发 和发生死亡的风险，提高患者疾病生存率，同时减少对不必要患者的治疗，并且 可以为其他肿瘤的 CIK 治疗提供新的思路。 关键词:CIK 细胞 急性白血病 过继性细胞免疫治疗 Meta 分析 4 万方数据 华 中 科 技 大 学 硕 士 学 位 论 文 Efficacy of Cytokine Induced Killer Cell for Acute Leukemia: A Meta-analysis Postgraduate: Qingyan Zhang Supervisor: Prof. Zhichao Chen Abstract Objective Chemotherapy and hematopoietic stem cell transplantation, are the two common methods of treatment of acute leukemia in clinical currently, however, due to the multidrug resistance of leukemia stem cell and the exist of minimal residual disease, are the main cause of refractory and relapsed of acute leukemia, the treatment’s effective are also deterred. Cytokine induced killer cells which is famous for its strong ability of anti-tumor, killing the tumor advantages. Many clinical trials have been carried out in succession at home and abroad for the treatment of malignant tumors, while the conclusion is not the same for each experiment. Therefore, we use statistical methods, by comparing the two ways of treatment for acute leukemia to investigate whether cytokine induced killer cell therapy is able to improve the therapeutic efficacy or not, some experimental datas were recorded. Methods We searched a systematic review of published papers from the sources of Pubmed(1979-2013), Embase(1974-2013), The Cochrane Library(1986-2013), Chinese Biomedical Literature Database(1998-2013) and other electronic databases, combined with manual retrieval methods. The clinical trials of